Gilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM EDTUBS analyst Marc Goodman lowered his price target on Gilead Sciences (NASDAQ: GILD) to $118.00 (from $130.00) following Q1 results but maintained a Buy rating.
Goddman commented, "We have lowered our HCV sales estimates to reflect lower ASPs (higher rebates to defend share from Merck's... More
Gilead Sciences (GILD) Receives Positive CHMP Opinion for Marketing Odefsey as HIV-1 Treatment
April 29, 2016 8:11 AM EDTOn 28 April 2016 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Odefsey, intended for the treatment of adults and adolescents infected with human immunodeficiency virus 1 (HIV 1). The applicant for this medicinal product is Gilead Sciences International Ltd. (Nasdaq: GILD).
Odefsey is a fixed-dose combination of three active substances,... More
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM EDTBMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following the HCV miss. The firm maintained a Market Perform rating, saying it increases the need for pipeline.
Somaiya commented, "Gilead reported 1Q16 EPS... More
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $135 on Gilead Sciences (NASDAQ: GILD) despite a top-line miss driven by weaker U.S. Hep C sales.
Skorney commented, "U.S. Hep C sales came in several hundred million dollars short of expectations.... More
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM EDTMaxim Group downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
Analyst Jason Kolbert highlighted:
Gilead reported quarterly results with total top-line revenues of $7.6B missing consensus of $7.7B by a hair. Non-GAAP quarterly net income was $4.3B or $3.03 per diluted share. The company ended the period with $21.3B in cash and $22B in debt.HCV revenues continue to drive Gilead but tough comps, the laws of growth (for big numbers), and... MoreGilead Sciences (GILD) Misses Q1 EPS by 10c
April 28, 2016 4:05 PM EDTGilead Sciences (NASDAQ: GILD) reported Q1 EPS of $3.03, $0.10 worse than the analyst estimate of $3.13. Revenue for the quarter came in at $7.8 billion versus the consensus estimate of $8.08 billion. Gilead Sciences reaffirmed FY2016 guidance.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
... More